Anna Kohlmann
Publications by Year
Research Areas
Computational Drug Discovery Methods, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Gastrointestinal Tumor Research and Treatment, Sarcoma Diagnosis and Treatment
Most-Cited Works
- → Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase(2016)396 cited
- → Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients(2014)159 cited
- → Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry(2020)109 cited
- → Fragment Growing and Linking Lead to Novel Nanomolar Lactate Dehydrogenase Inhibitors(2013)84 cited
- → Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening(2021)70 cited
- → Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery(2015)38 cited
- → The coupling effects of some thiol and other sulfur-containing compounds on the circadian rhythm of cell division in photosynthetic mutants of Euglena(1976)30 cited
- → Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models(2016)29 cited
- → Exploration of Cryptic Pockets Using Enhanced Sampling Along Normal Modes: A Case Study of KRAS G12D(2024)22 cited
- → Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non–small cell lung cancer(2022)22 cited